Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evofosfamide + Ipilimumab in Advanced Solid Tumors
NCT03098160Phase 1Unknown
- Sponsor
- Threshold Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evofosfamide in prostate cancer (PCa), pancreatic cancer (PC), melanoma and 1 more, sponsored by Threshold Pharmaceuticals. Primary endpoint: Recommended Phase 2 Dose. Status: unknown.
02
Drugs
evofosfamide
03
Conditions
prostate cancer (PCa)pancreatic cancer (PC)melanomasquamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03098160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098160.